- Home
- IDYA vs JANX Comparison
IDYA vs JANX Comparison
Compare IDYA & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- JANX
- Stock Information
- Founded
- IDYA 2015
- JANX 2017
- Country
- IDYA United States
- JANX United States
- Employees
- IDYA N/A
- JANX N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- IDYA Health Care
- JANX Health Care
- Exchange
- IDYA Nasdaq
- JANX Nasdaq
- Market Cap
- IDYA 1.5B
- JANX 1.6B
- IPO Year
- IDYA 2019
- JANX 2021
- Fundamental
- Price
- IDYA $17.42
- JANX $25.56
- Analyst Decision
- IDYA Strong Buy
- JANX Strong Buy
- Analyst Count
- IDYA 13
- JANX 7
- Target Price
- IDYA $53.58
- JANX $94.29
- AVG Volume (30 Days)
- IDYA 1.4M
- JANX 929.3K
- Earning Date
- IDYA 05-06-2025
- JANX 05-08-2025
- Dividend Yield
- IDYA N/A
- JANX N/A
- EPS Growth
- IDYA N/A
- JANX N/A
- EPS
- IDYA N/A
- JANX N/A
- Revenue
- IDYA $7,000,000.00
- JANX $9,336,000.00
- Revenue This Year
- IDYA $121.20
- JANX N/A
- Revenue Next Year
- IDYA $302.20
- JANX $250.58
- P/E Ratio
- IDYA N/A
- JANX N/A
- Revenue Growth
- IDYA N/A
- JANX 28.12
- 52 Week Low
- IDYA $13.45
- JANX $22.52
- 52 Week High
- IDYA $44.42
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- IDYA 43.87
- JANX 37.10
- Support Level
- IDYA $16.82
- JANX $24.13
- Resistance Level
- IDYA $21.43
- JANX $33.97
- Average True Range (ATR)
- IDYA 1.16
- JANX 2.01
- MACD
- IDYA -0.16
- JANX -0.61
- Stochastic Oscillator
- IDYA 13.02
- JANX 14.53
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.